mProX™ Human LY6G6D Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Immune Checkpoint Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human LY6G6D Stable Cell Line (S01YF-1023-PY199). Click the button above to contact us or submit your feedback about this product.
Taylor Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Casey Johnson (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Enhanced LY6G6D protein expression was observed in metastatic cell lines, where the highest levels of P-STAT5 were detected.
LY6G6D and CD15 were stained in RKO (MSI-H) and SW620 (MSS) cells, with green and red fluorescence, respectively. Basal activation of stat1, stat3, and stat5 was assessed in a panel of CRC cell lines in the lower right quadrant. In the lower left quadrant, the expression of P-STAT5, STAT5, P-ERK1/2, ERK1/2, and LY6G6D was examined via western blotting. Quantification of P-STAT5, P-ERK1/2, and LY6G6D relative to β-actin was performed in the lower right quadrant.
Ref: Giordano, Guido, et al. "JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer." Journal of Experimental & Clinical Cancer Research 38.1 (2019): 1-11.
Pubmed: 30670049
DOI: 10.1186/s13046-018-1019-5
Research Highlights
Giordano, Guido; Pancio, Massimo. "MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer." WIREs mechanisms of disease, 2023.
The majority of cancers, including colorectal cancer (CRC) with intact DNA mismatch repair, experience a suppressed immune response and resistance to immune checkpoint inhibitors. The MHC class III lymphocyte antigen 6G (LY6G) encodes glycosylphosphatidylinositol (GPI) proteins anchored to the membrane. LY6G proteins and snake venom neurotoxins contain a three-finger (3F) folding domain. Studies suggest that LY6 proteins, such as LY6G6D, may serve as effective tumor-associated antigens that can inhibit anti-tumor immunity in cancers with proficient mismatch repair. Therefore, they are referred to as MHC class III LY6G endogenous immunotoxins. In light of the discovery of LY6G6D as a tumor-associated antigen, T-cell engagers (TcEs) have been developed to simultaneously bind LY6G6D on cancer cells and CD3 on T cells, offering improved treatment options for individuals with metastatic solid tumors resistant to ICIs. This article presents a comprehensive understanding of how modifications in MHC class III genes influence antitumor immunity, and how this knowledge can be translated into effective therapies for patients who do not respond to standard immunotherapy.
Giordano, Guido; Pancio, Massimo. "MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer." WIREs mechanisms of disease, 2023.
Pubmed:
37818781
DOI:
10.1002/wsbm.1631
Corrales, Leticia. et al. "LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager." Frontiers in immunology, 2022.
Colorectal cancer (CRC) is a prevalent cancer affecting individuals globally and requires more advanced treatment approaches. Through examination of tumor genetic and molecular data, the researchers aimed to identify potential antigens unique to CRC cells and their potential for targeted cytotoxic T-cell therapy. Through this study, LY6G6D was identified as a promising tumor-specific antigen, primarily present in the microsatellite stable (MSS) subtype. A specialized anti LY6G6D/CD3 T cell engager (TcE) was developed and showed significant efficacy in killing CRC cells and activating T cells.
Corrales, Leticia. et al. "LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager." Frontiers in immunology, 2022.
Pubmed:
36159851
DOI:
10.3389/fimmu.2022.1008764
